Enfusion (NYSE:ENFN – Get Free Report)‘s stock had its “market perform” rating reaffirmed by equities research analysts at William Blair in a research report issued on Monday,Benzinga reports.
ENFN has been the topic of several other research reports. Stifel Nicolaus increased their target price on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Piper Sandler lifted their price objective on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research note on Monday, December 23rd. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $10.25.
View Our Latest Stock Analysis on ENFN
Enfusion Stock Performance
Insider Activity
In other Enfusion news, CEO Oleg Movchan sold 2,771 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $28,070.23. Following the completion of the transaction, the chief executive officer now owns 526,702 shares in the company, valued at approximately $5,335,491.26. This represents a 0.52 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Neal Pawar sold 21,801 shares of Enfusion stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the sale, the chief operating officer now directly owns 1,143,544 shares in the company, valued at $11,469,746.32. This represents a 1.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 56,404 shares of company stock worth $580,130 in the last 90 days. Corporate insiders own 36.44% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of ENFN. Centiva Capital LP boosted its position in Enfusion by 5.0% during the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock worth $243,000 after acquiring an additional 1,227 shares during the last quarter. Harbor Capital Advisors Inc. lifted its position in shares of Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after purchasing an additional 1,315 shares in the last quarter. Azora Capital LP boosted its holdings in Enfusion by 6.8% during the third quarter. Azora Capital LP now owns 29,827 shares of the company’s stock worth $283,000 after purchasing an additional 1,890 shares during the last quarter. 272 Capital LP grew its position in Enfusion by 1.5% in the second quarter. 272 Capital LP now owns 139,180 shares of the company’s stock valued at $1,186,000 after purchasing an additional 2,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Enfusion by 27.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after buying an additional 4,239 shares during the last quarter. 81.05% of the stock is currently owned by institutional investors.
About Enfusion
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
See Also
- Five stocks we like better than Enfusion
- What is a Bond Market Holiday? How to Invest and Trade
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- ESG Stocks, What Investors Should Know
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.